Phone: (212) 746-5788
Fax: (212) 746-0975
Urology
- Adrenal Cancer
- Kidney Cancer
- Bladder Cancer
- Prostate Cancer
- Ureteral Cancer
- Testicular Cancer
- Urologic Sarcoma
Procedures
- Adrenalectomy
- Nephrectomy
- Robotic Cystectomy
- Robotic Prostatectomy
- Ureteral Cancer Treatment
- Testicular Cancer Treatment
- Urologic Sarcoma Treatment
Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the Bladder
Eric B. Smith, Michael Schwartz, Hideki Kawamoto, Xueke You, David Hwang, HuixEric B. Smith, Michael Schwartz, Hideki Kawamoto, Xueke You, David Hwang, Huixian Liu and Douglas S. Scherr
From the Department of Urology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York
View PDF**
Purpose: Imidazoquinolines (Toll-like receptor-7 agonists) are a class of synthetic immune modulating agents. Imiquimod, a member of this drug family, is currently used as ?rst line topical therapy for genital condyloma. It recently showed clinical ef?cacy against several benign and malignant skin lesions, including actinic keratosis and basal cell carcinoma. Working primarily through the stimulation of a proin?ammatory immune response, the mechanism of action of imiquimod may be similar to that through which bacillus Calmette-Guerin is thought to act. We hypothesized that imidazoquinolines have therapeutic potential against bladder cancer. We determined the in vitro and in vivo effects of imidazoquinolines against bladder cancer cells.
Materials and Methods: The human and murine J82, T24, TCC-SUP (American Tissue Culture Collection, Manassas, Virginia) and MBT-2 bladder cancer cell lines were cultured in normal culture medium or medium supplemented with imidazoquinoline. Effects on cell viability, apoptosis induction and cytokine production were evaluated. In addition, the effects of imidazoquinoline on in vivo bladder tumor growth were determined via intravesical instillation in an orthotopic bladder tumor model in the mouse.
Results: A dose dependent decrease in cell viability was observed in all tumor cell lines treated with imidazoquinoline. In addition, imidazoquinoline signi?cantly induced apoptosis and cytokine production. In in vivo experiments most mice treated with imidazoquinoline showed only an intense in?ammatory response with no evidence of tumor, while control mice showed tumor growth.
Conclusions: Imidazoquinolines have potent direct activity against bladder cancer cells by decreasing cell viability and inducing apoptosis and cytokine production. In addition, in vivo data suggest antitumor effects in an orthotopic bladder cancer mouse model. Therefore, imidazoquinolines may have therapeutic potential as a synthetic intravesical agent against bladder cancer.
**PDF contains complete article.